Mutations of the BCL10 gene are not associated with the blast crisis of chronic myeloid leukaemia

TO THE EDITOR
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder associated in over 95% of the cases with the presence of the BCR-ABL hybrid gene in multipotential haemopoietic precursors. BCR-ABL encodes a 210 kDa fusion protein with enhanced tyrosine kinase activity 1, 2 and may underlie most if not all phenotypic abnormalities of the chronic phase (CP) of CML. 3 The invariable evolution of the disease to a fatal blast crisis (BC), often preceded by a transitional period called accelerated phase (AP), is believed to be due to acquisition of additional genetic changes in the leukemic clone. 4 However, the few known abnormalities [5] [6] [7] [8] account for less than 30% of the BC and the cause for the drastic phenotypic change of the disease in the majority of CML patients is still unknown. Since no assay that reliably discriminates between the genotypes of CP and BC cells has yet been developed, the search for causative abnormalities has concentrated on the testing of relevant candidate genes. These have generally been selected among genes that (1) are associated with essential cellular pathways such as control of the cell cycle, differentiation or apoptosis, and/or (2) have been implicated in other malignancies.
The BCL10 gene has been recently cloned 9, 10 as the translocation partner of the immunoglobulin heavy chain (IgH) locus in the t(1;14)(p22;q32) chromosomal translocation, an abnormality associated with low-grade mucosa-associated lymphoma tissue (MALT)-B cell lymphomas. Located on chromosome 1p22, BCL10 shows recurrent breakpoints in the 5Ј region, which fuses to the J6 region of the IgH gene in a head to head fashion on the derivative chromosome 14. The BCL10 gene is the cellular homolog of the equine herpesvirus-2 E10 gene. The BCL10 protein, like E10 and many others that are involved in apoptotic processes, contains a CARD at its amino-terminus and has been shown to be capable of inducing apoptosis. 9, 10 In addition to its involvement in the t(1;14) of MALT-B lymphomas, BCL10 was initially reported as a frequent target gene for mutation in various neoplasms, including other types of lymphoma and non- haematologic malignancies. 9 The latter findings have however been unconfirmed in several recent studies. [11] [12] [13] [14] [15] [16] In this study, we have investigated the potential involvement of BCL10 gene mutations in the blastic transformation of CML by mutational analysis of CML cell lines and patient samples. We show here that BCL10 is a highly polymorphic gene, but that no functional mutation or increased frequency of specific allelotypes is associated with CML.
Fifty-six patients with CML in blast crisis (19 myeloid, 24 lymphoid, 13 of unknown lineage) and one patient in accelerated phase were included in the present study. Total leucocyte DNA was isolated from heparinized peripheral blood samples after red cell lysis by standard methods. Genomic DNA from 13 CML (AR230, BV173, CMLT-1, EM2, EM3, GDM1, K562, KCL22, KU812, KYO1, LAMA-84, MEG-01, NALM-1) and one acute lymphoblastic leukaemia (ALL) (SD-1) cell lines was also analysed. Control DNA from 92 normal subjects was extracted from peripheral blood leucocytes or buccal epithelium. All specimens were obtained after informed consent.
The complete coding region of the BCL10 gene was amplified in five different polymerase chain reactions (PCR) encompassing exon 1 and two overlapping fragments for each exon 2 and 3 ( Figure 1 ). The PCR primers were based on those described elsewhere, 9 except for some slight modifications (Table 1) . Each reaction was seeded with 50-100 ng genomic DNA and amplification was carried out for 30 cycles on a MJ Research thermal cycler (MJ Research, GRI, Essex, UK) under conditions tested as suitable for each primer pair ( Table 1) . Composition of the PCR reaction and thermocycling parameters were essentially as previously described. 17 For single-strand conformation polymorphism (SSCP) analysis, the PCR products were labeled with ␣ 32 P-dCTP using three additional cycles of amplification, heatdenatured and electrophoresed on 6-8% polyacrylamide/glycerol gels. Abnormally migrating bands were excised from the gel, purified, reamplified and subcloned into a pCR2.1 TA cloning vector (Invitrogen, Groningen, The Netherlands). Clones were further selected by electrophoresis on polyacrylamide/glycerol gels and those with differently migrating bands were sequenced with fluorescently labelled M13 primers.
No leukaemia-associated BCL10 mutation was observed in any of the CML cell lines or patient samples studied. For the exon 1-including 184-bp fragment, four distinct allelic variants represented by five differently migrating bands were found. Two of these variants were
Figure 1
Schematic representation of the BCL10 gene showing location of the primers used in the PCR/SSCP analysis in relation to the 3 exons (e1, e2 and e3), introns, and 5Ј and 3Ј UTRs. Double-headed arrows with numbers on top indicate the size (in bp) of the PCR products. due to intronic nucleotide (nt) substitutions (5829 G → C and 5835 G → C), and two were substitutions in the exon. One of the exonic nucleotide changes, at codon 8 (CTC → CTG), did not alter the amino acid, whereas the other alteration, a transversion from G → T at codon 5 (GCA → TCA), resulted in a non-conservative amino acid change from alanine to serine, a hydrophobic to a relatively hydrophilic molecule. The difference in mobility between the wild-type and the intronic 5835G → C variant was subtle on SSCP gels and the genotypes were further confirmed by restriction fragment length polymorphism, since the substitution introduced a BsmAI site. The 3Ј fragment (263 bp) of exon 3 showed a rarer polymorphic variant differing from the more common allele by a G → A transversion at codon 213 resulting in a non-conserved amino acid alteration from glycine to glutamic acid. Table 2 shows the frequencies of the allelic variants in the normal and CML populations. No altered mobility was detected in either of the two PCR products (237 and 244 bp, respectively) spanning exon 2 or in the 263 bp 5Ј fragment of exon 3. The two amino acid changes in exon 1 and 3, respectively, were reported earlier from RT-PCR analysis of t(1;14) positive MALT-B lymphoma patients. 11 The effect of these changes, proximal and distal to the CARD domain respectively, on protein folding cannot be predicted at this stage. It is unlikely, however, that these polymorphisms have any functional consequence since they were also present in the normal population at frequencies comparable to those among the CML group. This suggests that there is no preferential selection/predisposition of any BCL10-specific allele type in the generation of CML.
The inability of the present study to find mutations in the BCL10 gene is not likely to be technical since the same assay, PCR-SSCP, was used in the original study where several mutations were detected in cells from other malignancies. 9 Furthermore, our assay was able to identify various allelic variants in CML, as well as in normal individuals. Incidentally, we and others [11] [12] [13] [14] 16 were able to demonstrate that some of the codon changes reported as mutations by Zhang et al 10 in MALT-B lymphomas are in fact sequence polymorphisms in the general population. It is also interesting to note that following the initial report by Willis et al, 9 several other groups have screened tumours other than MALT B cell lymphomas and failed to detect any abnormality. [11] [12] [13] [14] [15] [16] The notably high frequency of mutations in the BCL10 gene in MALT-B and other B-and T-lymphomas suggests that truncation of this pro-apoptotic protein may have a crucial role in the generation of primary lymphoid malignancies. The absence of these mutations in blast crisis of CML, a third of which are of lymphoid origin, may indicate that the BCR-ABL oncogenic signal overrides any potential survival advantage imparted on a CML clone by a BCL10 mutation.
